CJC-1295 DAC 2mg

CJC-1295 is a synthetic analogue of growth hormone releasing hormone (GHRH) that increases plasma levels of growth hormone and insulin-like growth factor 1 (IGF-1). DAC is an additive moiety that prolongs the plasma half-life of CJC-1295.

Properties

• • Chemical Formula: C152H252N44O42
  • Molecular Mass: 3647.28
  • Synonyms: CJC1295 Without DAC, CJC1295 With DAC, 446262-90-4
  • Molar Mass: 3367.9
  • CAS Number: 446036-97-1
  • PubChem: 91976842
  • Total Amount of the Active Ingredient: 2mg (1 vial)
  • Shelf Life: 36 months

•  GROWTH HORMONE RELEASE
  The peptide is intended to trigger the release of GH, as it is a synthetic analog for the natural GHRH. Mice model experiments have reported that a single administration of the peptide may induce almost 2-10 times higher production of GH^[3]. GH expression appears to reach a maximum level after 2 hours of the peptide administration, and the effect is maintained up to about six days later. The peptide appears to maintain the natural physiological level of GH, unlike other secretagogues. In other words, CJC-1295 has the potential to perform as a physiological GHRH and maintain the natural biological high and low expression pattern in GH levels. CJC-1295 appears to maintain the physiological level of the hormone while enhancing its release in the blood. This effect would ensure that GH brings about the benefits without enhancing its adverse side effects. CJC-1295 has been studied in relation to physiological regulation of GH on protein synthesis, fat metabolism, blood sugar, hypertrophy, bone density, hyperplasia, and myocardial function.
• GROWTH
  Research has suggested that CJC-1295 may restore the physiological release of GH in mice lacking normal GH physiology^[5]. Jette et al. notes that “CJC-1295, showed a 4-fold increase in GH area under the curve over a 2-h period.” The peptide may potentially be used to treat growth anomalies in different mammalian species. Maintenance of the circadian cycle of GH release happens to be crucial to bringing about appropriate production of downstream hormones, such as insulin-like growth factor-1 (IGF-1).
• INFERTILITY
  Studies from the early 1990s suggest that CJC-1295 and other GRF analogs may improve female infertility. Mice models of superovulation have proven that GH and IGF-1 levels increase in blood around the time of ovulation^[4]. Thus the treatment, including CJC-1295 and GRF analogs may promote ovulation in female patients, possibly through IGF-1 and GH expression cycle. The use of GH secretagogues like CJC-1295 may be sufficient to promote proper ovulation. Scientists have further suggested the use of these analogs to improve sperm production and thus treat male infertility, though proper research is required to test the hypothesis.

Product Quality

Lab tests are occasionally published on the website.

You can have the product you bought from us tested at any HPLC licensed testing facility and if the results are negative, we will refund the following:

• • Cost of HPLC test
  • Total amount of the order + shipping fee

Disclaimer

The information provided above is not intended to substitute medical advice, diagnosis, or treatment. Should you have any questions regarding a medical condition, seek the advice of your physician or a qualified healthcare provider. In no case should medical advice be disregarded or delayed because of what you have read or seen. We bear no responsibility or liability for your use of any of our research compounds and products. Please note that they are being sold for research purposes ONLY. We do NOT condone any personal use.